The Molecular, Genetic, Pathological Basis and Clinical Perspectives of Endometrial Cancer: A Narrative Review
International Journal of Molecular Sciences · 24.10.2026 · 27 (21) · 9511
DOI: 10.3390/ijms27219511 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 24.10.2026. Verfasst von Chia-Ling Chang und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Education, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 23142, Taiwan. Hauptthemen laut MEDLINE: Endometrial Neoplasms. Die Arbeit nennt 128 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taipei Tzu Chi Hospital.
Abstract (Originalsprache)
Endometrial cancer (EC) is the most common gynecologic malignancy in high-income regions, with a rising global incidence driven by population aging and obesity. Management of EC is undergoing a paradigm shift from traditional histopathological classification (Bokhman Types I and II) to a molecularly integrated model. Key driver alterations include mutations in PTEN, PIK3CA, PIK3R1, ARID1A, KRAS, and TP53, alongside focal amplifications of CCNE1 and ERBB2, all of which drive oncogenesis through dysregulation of the PI3K/AKT/mTOR, Wnt/β-catenin, MAPK/ERK, and p53 signaling cascades. Integrated genomic profiling via The Cancer Genome Atlas (TCGA) and practical surrogates like ProMisE classifies EC into four distinct molecular subgroups: POLE-ultramutated (POLEmut), mismatch repair-deficient (MMRd/MSI-H), copy-number low/non-specific molecular profile (NSMP), and copy-number high/p53-abnormal (p53abn). These subgroups display unique biological features, tumor microenvironments, and prognostic trajectories, and have been formally incorporated into the FIGO 2023 staging system. Crucially, molecular classification directly informs biomarker-driven systemic management. MMRd may predict profound responses to immune checkpoint inhibitors (e.g., pembrolizumab, dostarlimab) in both frontline and recurrent settings. For MMR-proficient disease, combination strategies such as anti-angiogenic/immunotherapy (lenvatinib plus pembrolizumab), hormone/mTOR or CDK4/6 inhibitor combinations, and nuclear export inhibitors (selinexor in TP53 wild-type) seem to offer substantial benefit. Furthermore, novel modalities including HER2-targeted antibody-drug conjugates (trastuzumab deruxtecan), PARP inhibitors, and G2/M checkpoint inhibitors (adavosertib) are actively expanding the therapeutic armamentarium. Integrating multi-omics techniques, artificial intelligence, and novel systemic therapies into clinical workflows emerge to refine risk stratification, avoid over- or undertreatment, and establish a new standard of precision oncology in endometrial cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Education, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, Taipei 23142, Taiwan.
- School of Medicine, College of Medicine, MacKay Medical University, New Taipei City 25245, Taiwan.
- Department of Obstetrics and Gynecology, Taipei Tzu-Chi Hospital, The Buddhist Tzu-Chi Medical Foundation, New Taipei City 23142, Taiwan.
- School of Medicine, Tzu-Chi University, Hualien 97004, Taiwan.
ORCID-Profile: Kuo-Hu Chen
Förderung
- Taipei Tzu Chi Hospital
Zitieren
APA
Chang, C. L., Chen, J. H., & Chen, K. H. (2026). The Molecular, Genetic, Pathological Basis and Clinical Perspectives of Endometrial Cancer: A Narrative Review. International Journal of Molecular Sciences, 27(21), 9511. https://doi.org/10.3390/ijms27219511
Vancouver
Chang CL, Chen JH, Chen KH. The Molecular, Genetic, Pathological Basis and Clinical Perspectives of Endometrial Cancer: A Narrative Review. International Journal of Molecular Sciences. 2026;27(21):9511. doi:10.3390/ijms27219511
BibTeX
@article{Chang2026,
author = {Chang, Chia-Ling and Chen, Jie-Hong and Chen, Kuo-Hu},
title = {The Molecular, Genetic, Pathological Basis and Clinical Perspectives of Endometrial Cancer: A Narrative Review},
journal = {International Journal of Molecular Sciences},
year = {2026},
volume = {27},
number = {21},
pages = {9511},
doi = {10.3390/ijms27219511}
}
EUVIMED